

Please amend the application as follows:

IN THE CLAIMS

Please cancel claims 5, 7, 8, 10-12, 21-23, 25-27, 32-46, 51-53, 55-57, and 62-96;

Please amend claims 1, 17 and 47 as follows:

Listing of the Claims:

1. (Currently Amended) A method for diminishing, inhibiting or eliminating addiction-related behavior of a mammal, wherein said method comprises administering to said mammal an effective amount of a composition ~~that increases central nervous system GABA levels in said mammal~~ consisting essentially of topiramate or a pharmaceutically acceptable salt thereof, or an enantiomer or racemic mixture thereof.
2. (Original) A method according to claim 1, wherein said addiction-related behavior is diminished, inhibited or eliminated without an aversive response to said composition.
3. (Original) A method according to claim 1, wherein said addiction-related behavior is diminished, inhibited or eliminated without an appetitive response to said composition.
4. (Original) A method according to claim 1, wherein said addiction-related behavior is diminished, inhibited or eliminated without an alteration in locomotor function of said mammal.
5. Cancelled.
6. (Original) A method according to claim 1, wherein said addiction related behavior is conditioned place preference.
- 7-8. Cancelled.
9. (Original) A method according to claim 1, wherein said topiramate is administered in an amount of about 25mg to about 1g/day.

10-12. Cancelled.

13. (Original) A method according to claim 1, wherein said composition is not addictive to said mammal.

14. (Original) A method according to claim 1, wherein said mammal is a primate.

15. (Original) A method according to claim 1, wherein said drug of abuse is selected from the group consisting of pshychostimulants, narcotic analgesics, alcohols, addictive alkaloids or combinations thereof.

16. (Original) A method according to claim 1, wherein said drug of abuse is selected from the group consisting of cocaine, nicotine, methamphetamine, morphine, heroin, ethanol, phencyclidine, methylenedioxymethamphetamine, or combinations thereof.

17. (Currently Amended) A method for diminishing, inhibiting or eliminating cravings associated with addiction to drugs of abuse in a mammal, wherein said method comprises administering to said mammal an effective amount of a composition ~~that increases central nervous system GABA levels in said mammal~~ consisting essentially of topiramate or a pharmaceutically acceptable salt thereof, or an enantiomer or racemic mixture thereof.

18. (Original) A method according to claim 17, wherein said cravings are diminished, inhibited or eliminated without an aversive response to said composition.

19. (Original) A method according to claim 17, wherein said cravings are diminished, inhibited or eliminated without an appetitive response to said composition.

20. (Original) A method according to claim 17, wherein said cravings are diminished, inhibited or eliminated without an alteration in locomotor function of said mammal.

21-23. Cancelled.

24. (Original) A method according to claim 17, wherein said topiramate is administered in an amount of about 25mg to about 1g/day.

25-27. Cancelled.

28. (Original) A method according to claim 17, wherein said mammal is a primate.

29. (Original) A method according to claim 17, wherein said composition is not addictive to said mammal.

30. (Original) A method according to claim 17, wherein said drug of abuse is selected from the group consisting of pshychostimulants, narcotic analgesics, alcohols, addictive alkaloids or combinations thereof.

31. (Original) A method according to claim 17, wherein said drug of abuse is selected from the group consisting of cocaine, nicotine, methamphetamine, morphine, heroin, ethanol, phencyclidine, methylenedioxymethamphetamine, or combinations thereof.

32-46. Cancelled.

47. (Currently Amended) A method for diminishing, inhibiting or eliminating dependency characteristics associated with addiction to drugs of abuse in a mammal, wherein said method comprises administering to said mammal an effective amount of a composition that increases central nervous system GABA levels in said mammal consisting essentially of topiramate, or a pharmaceutically acceptable salt thereof, or an enantiomer or racemic mixture thereof.

48. (Original) A method according to claim 47, wherein said dependency characteristics are diminished, inhibited or eliminated without an aversive response to said composition.

49. (Original) A method according to claim 47, wherein said dependency characteristics are diminished, inhibited or eliminated without an appetitive response to said composition.

50. (Original) A method according to claim 47, wherein said dependency characteristics are diminished, inhibited or eliminated without an alteration of locomotor function in said mammal.

51-53. Cancelled.

54. (Original) A method according to claim 47, wherein said topiramate is administered in an amount of about 25mg to about 1g/day.

55-57. Cancelled.

58. (Original) A method according to claim 47, wherein said mammal is a primate.

59. (Original) A method according to claim 47, wherein said composition is not addictive to said mammal.

60. (Original) A method according to claim 47, wherein said drug of abuse is selected from the group consisting of pshychostimulants, narcotic analgesics, alcohols, addictive alkaloids or combinations thereof.

61. (Original) A method according to claim 47, wherein said drug of abuse is selected from the group consisting of cocaine, nicotine, methamphetamine, morphine, heroin, ethanol, phencyclidine, methylenedioxymethamphetamine, or combinations thereof.

62-96. Cancelled.